Obesity

Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity

Diabetes Obes MetabPublished Retrospective cohort study

Main finding · Suicide-related eventsResult — go to the resultHazard ratio 0.74 95% CI 0.57–0.95

Authors' conclusion

Among adolescents with obesity, incretin-based therapy was not associated with increased psychiatric risk and was associated with lower risks of suicide-related events, suicidal ideation, and anxiety compared with lifestyle intervention.

Study context

Population
Adolescents with overweight or obesitypropensity score matched
Participants
9,222 vs 9,222
Exposure
Incretin-based therapy vs lifestyle intervention
  • Incretin-based therapyn = 9,222
  • Lifestyle interventionn = 9,222reference
Outcome
Suicide-related events:
  • Suicidal ideation
  • Suicide attempt
Follow-up
30 days to 1095 days after the index date
Methodological detailspropensity score matching, TriNetX Global Collaborative Network electronic health records
  • Propensity score matching
  • TriNetX Global Collaborative Network electronic health records

Main finding

Suicide-related events

Hazard ratio

0.74

95% CI 0.57–0.95

Incretin-based therapyvs Lifestyle intervention
HR 0.74 (95% CI 0.57–0.95)

As reported in the abstract

Observational data: associations, not effects.

Secondary outcomes

OutcomeHR (95% CI)
Suicidal ideation · 30 to 1095 days after index datePropensity score matched0.73 (0.56–0.96)
Anxiety · 30 to 1095 days after index datePropensity score matched0.92 (0.84–0.99)

Suicide attempt, insomnia, depression and eating disorders · 30 to 1095 days after index date

No significant differences for suicide attempt, insomnia, depression or eating disorders

Suicide-related events, female adolescents (subgroup)

Risk reduction significant among female adolescents: HR
0.61 (0.46-0.82) (95% CI)

Suicide-related events, adolescents without T2D (subgroup)

Risk reduction significant among those without T2D: HR
0.63 (0.47-0.85) (95% CI)

Suicide-related events, males and those with T2D (subgroups)

Risk reductions not significant among males or those with T2D

Sensitivity analyses

Sensitivity analyses supported the primary findings

Original publication

Psychiatric Safety of GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists in Adolescents With Obesity. Diabetes Obes Metab. Published 14 September 2026. doi:10.1111/dom.71353

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.